GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (NAS:POAI) » Definitions » PE Ratio (TTM)

POAI (Predictive Oncology) PE Ratio (TTM) : At Loss (As of Dec. 14, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Predictive Oncology PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-12-14), Predictive Oncology's share price is $0.7799. Predictive Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.05. Therefore, Predictive Oncology's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Predictive Oncology's PE Ratio (TTM) or its related term are showing as below:

POAI' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



POAI's PE Ratio (TTM) is ranked worse than
100% of 400 companies
in the Medical Devices & Instruments industry
Industry Median: 29.01 vs POAI: At Loss

Predictive Oncology's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-0.48. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.05.

As of today (2024-12-14), Predictive Oncology's share price is $0.7799. Predictive Oncology's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.26. Therefore, Predictive Oncology's PE Ratio without NRI for today is At Loss.

Predictive Oncology's EPS without NRI for the three months ended in Sep. 2024 was $-0.36. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.26.

During the past 3 years, the average EPS without NRI Growth Rate was 48.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 56.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 49.10% per year.

During the past 13 years, Predictive Oncology's highest 3-Year average EPS without NRI Growth Rate was 68.70% per year. The lowest was -64.20% per year. And the median was 45.80% per year.

Predictive Oncology's EPS (Basic) for the three months ended in Sep. 2024 was $-0.48. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.05.


Predictive Oncology PE Ratio (TTM) Historical Data

The historical data trend for Predictive Oncology's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology PE Ratio (TTM) Chart

Predictive Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Predictive Oncology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Predictive Oncology's PE Ratio (TTM)

For the Medical Instruments & Supplies subindustry, Predictive Oncology's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Predictive Oncology's PE Ratio (TTM) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's PE Ratio (TTM) falls into.



Predictive Oncology PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Predictive Oncology's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=0.7799/-3.050
=At Loss

Predictive Oncology's Share Price of today is $0.7799.
Predictive Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.05.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Predictive Oncology  (NAS:POAI) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Predictive Oncology PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Predictive Oncology Business Description

Traded in Other Exchanges
N/A
Address
No.91 43rd Street, Suite 110, Pittsburgh, PA, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
Executives
Robert L Myers officer: CHIEF FINANCIAL OFFICER 4765 BEACON HILL ROAD, EAGAN MN 55122
Nuzum Charles Lee Sr director 633 1ST STREET WEST, SONOMA CA 95476
Veena Rao director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Matthew Hawryluk director C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
St. Clair Gregory Sr director 1645 WHITLEY DRIVE, HARRISBURG PA 17111
Nancy Chung-welch director P O BOX 1572, PEPPERELL MA 01463
Pamela Bush officer: Chief Business Officer 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Daniel E Handley director 1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765
Raymond F Vennare director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
David Stewart Smith director 151 WASHINGTON STREET, PITTSBURGH PA 15218
J Melville Engle director 1 REMINGTON COURT, NAPA CA 94558
Jenkins Christina Lee Md director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Carl I. Schwartz 10 percent owner 20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180
Richard L Gabriel director 900 COCOANUT AVENUE, SARASOTA FL 34236
Pamela S Prior director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121